Enhancer of Revascularization, Gene and Stem Cell Therapies

Tokunaga, Koji; Date, Isao

doi:10.1007/978-4-431-99703-0_48

Cited by 1 publication

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These blood vessels narrow in people with MMD, which can eventually induce blockages, ischemic stroke, hemorrhagic stroke, and seizures. Nishimoto's disease was the term given to MMD in Europe following the presentation of the first countrywide data reported by Nishimoto et al at the Symposium Neuroradiologicum in Paris in 1967 [11]. The term "moyamoya disease" has gained acceptance in the international community since Suzuki et al published it in the English literature in 1969 [3].…”

Section: Review Search Methodologymentioning

confidence: 99%

“…While vascular abnormalities can occur in neurofibromatosis type-1, they differ from those seen in MMD [13,14]. TBI can cause damage to blood vessels in the brain, but the resulting vascular changes and symptoms are typically different from those seen in MMD [11].…”

Section: Feature Descriptionmentioning

confidence: 99%

“…CT angiography (CTA) offers fast acquisition of high-resolution images, making it useful for emergencies or patients unable to undergo MRI. It provides a detailed visualization of vascular anatomy [11,22]. Exposure to ionizing radiation and potential contrast-induced nephropathy are concerns.…”

Section: Ct Angiographymentioning

confidence: 99%

“…Anesthesia can impact cerebral perfusion pressure and blood flow regulation, which may exacerbate Moyamoya patients' already compromised cerebral circulation [19]. Anesthesia can cause blood pressure and heart rate fluctuations, which may further jeopardize cerebral perfusion in patients with already compromised circulation [11,22].…”

Section: Cerebral Perfusion and Hemodynamic Instabilitymentioning

confidence: 99%

See 3 more Smart Citations

Moyamoya Disease: Advances in Diagnosis, Treatment, and Surgical Interventions

Navandhar,

Gharde,

Shinde

et al. 2024

Cureus

View full text Add to dashboard Cite

Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by progressive narrowing of the brain's arteries, leading to an increased risk of stroke. The primary susceptibility gene, RNF213, has been identified in individuals of East Asian descent, contributing to ongoing research into potential therapeutic targets. The distinction between idiopathic MMD and secondary forms, such as Moyamoya syndrome (MMS), is discussed, focusing on associated conditions and risk factors. Surgical revascularization emerges as the mainstay of treatment, with direct, indirect, and combination bypass procedures explored. The review delves into advancements in imaging technology for diagnosis and treatment planning, emphasizing noninvasive magnetic resonance examination's role in identifying asymptomatic patients. Additionally, insights into anesthetic care and therapeutic approaches underscore the evolving understanding of this complex disease. The presented information aims to contribute to the ongoing dialogue surrounding MMD, providing a valuable resource for clinicians and researchers.

show abstract

Section: Review Search Methodologymentioning

confidence: 99%